REFERENCES
Ahmad M, Zeitlin IJ, Parratt JR, Pitt AR (2006). Degradation of bradykinin, a cardioprotective substance, during a single passage through isolated rat-heart. Archives of pharmacal research29: 241-248.
Amaral FA, Bastos LF, Oliveira TH, Dias AC, Oliveira VL, Tavares LD, et al. (2016). Transmembrane TNF-alpha is sufficient for articular inflammation and hypernociception in a mouse model of gout.European journal of immunology 46: 204-211.
Bakhle YS (1968). Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung. Nature 220: 919-921.
Campbell DJ (2013). Bradykinin Peptides. In: Kastin AJ (ed).Handbook of Biologically Active Peptides , 2nd edn. p^pp 1386-1393.
Cayla C, Labuz D, Machelska H, Bader M, Schafer M, Stein C (2012). Impaired nociception and peripheral opioid antinociception in mice lacking both kinin B1 and B2 receptors. Anesthesiology116: 448-457.
Chan WC, White PD (2000). Fmoc Solid Phase Peptide Synthesis - A Practical Approach . edn. Oxford University Press.
Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, et al. (2010). Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. The New England journal of medicine363: 532-541.
Curtis MJ, Alexander S, Cirino G, Docherty JR, George CH, Giembycz MA, et al. (2018). Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers. British journal of pharmacology 175: 987-993.
Elliott DF, Horton EW, Lewis GP (1960). Actions of pure bradykinin.The Journal of physiology 153: 473-480.
Ferreira SH (1965). A Bradykinin-Potentiating Factor (Bpf) Present in the Venom of Bothrops Jararca. British journal of pharmacology and chemotherapy 24: 163-169.
Ferreira SH, Vane JR (1967). The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. British journal of pharmacology and chemotherapy 30: 417-424.
Ferreira SH, Greene LH, Alabaster VA, Bakhle YS, Vane JR (1970). Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme. Nature 225: 379-380.
Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK, et al. (2020). A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. eLife 9.
Gomes ER, Lara AA, Almeida PW, Guimaraes D, Resende RR, Campagnole-Santos MJ, et al. (2010). Angiotensin-(1-7) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3’,5’-cyclic monophosphate-dependent pathway. Hypertension55: 153-160.
Guatimosim S, Amaya MJ, Guerra MT, Aguiar CJ, Goes AM, Gomez-Viquez NL, et al. (2008). Nuclear Ca2+ regulates cardiomyocyte function.Cell calcium 44: 230-242.
Guyenet PG (2006). The sympathetic control of blood pressure.Nature reviews. Neuroscience 7: 335-346.
Habal FM, Movat HZ (1976). Kininogens of human plasma. Seminars in thrombosis and hemostasis 3: 27-42.
Hasan AA, Amenta S, Schmaier AH (1996). Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation. Circulation 94: 517-528.
Heusch G, Botker HE, Przyklenk K, Redington A, Yellon D (2015). Remote ischemic conditioning. Journal of the American College of Cardiology 65: 177-195.
Jesus ICG, Scalzo S, Alves F, Marques K, Rocha-Resende C, Bader M, et al. (2018). Alamandine acts via MrgD to induce AMPK/NO activation against ANG II hypertrophy in cardiomyocytes. American journal of physiology. Cell physiology 314: C702-C711.
Kempe S, Fois G, Brunner C, Hoffmann TK, Hahn J, Greve J (2020). Bradykinin signaling regulates solute permeability and cellular junction organization in lymphatic endothelial cells. Microcirculation27: e12592.
Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010). Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS biology 8: e1000412.
Kopylov AT, Myasoedov NF, Dadayan AK, Zgoda VG, Medvedev AE, Zolotarev YA (2016). Use of deuterium labeling by high-temperature solid-state hydrogen-exchange reaction for mass spectrometric analysis of bradykinin biotransformation. Rapid communications in mass spectrometry : RCM 30: 1283-1294.
Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL (2005). International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacological reviews 57: 27-77.
Lilley E, Stanford SC, Kendall DE, Alexander SPH, Cirino G, Docherty JR, et al. (2020). ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020. British journal of pharmacology 177: 3611-3616.
Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
Marceau F, Bachelard H, Bouthillier J, Fortin JP, Morissette G, Bawolak MT, et al. (2020). Bradykinin receptors: Agonists, antagonists, expression, signaling, and adaptation to sustained stimulation.International immunopharmacology 82: 106305.
Marshall P, Heudi O, McKeown S, Amour A, Abou-Shakra F (2002). Study of bradykinin metabolism in human and rat plasma by liquid chromatography with inductively coupled plasma mass spectrometry and orthogonal acceleration time-of-flight mass spectrometry. Rapid communications in mass spectrometry : RCM 16: 220-228.
McEachern AE, Shelton ER, Bhakta S, Obernolte R, Bach C, Zuppan P, et al. (1991). Expression cloning of a rat B2 bradykinin receptor.Proceedings of the National Academy of Sciences of the United States of America 88: 7724-7728.
Menke JG, Borkowski JA, Bierilo KK, MacNeil T, Derrick AW, Schneck KA, et al. (1994). Expression cloning of a human B1 bradykinin receptor. The Journal of biological chemistry 269:21583-21586.
Morinelli TA, Webb JG, Jaffa AA, Privitera PJ, Margolius HS (2001). A metabolic fragment of bradykinin, Arg-Pro-Pro-Gly-Phe, protects against the deleterious effects of lipopolysaccharide in rats. The Journal of pharmacology and experimental therapeutics 296: 71-76.
Murphey LJ, Hachey DL, Oates JA, Morrow JD, Brown NJ (2000). Metabolism of bradykinin In vivo in humans: identification of BK1-5 as a stable plasma peptide metabolite. The Journal of pharmacology and experimental therapeutics 294: 263-269.
Oldenburg O, Qin Q, Krieg T, Yang XM, Philipp S, Critz SD, et al.(2004). Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection.American journal of physiology. Heart and circulatory physiology286: H468-476.
Orfanos SE, Langleben D, Khoury J, Schlesinger RD, Dragatakis L, Roussos C, et al. (1999). Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in humans. Circulation99: 1593-1599.
Park WK, St-Pierre SA, Barabe J, Regoli D (1978). Synthesis of peptides by the solid-phase method. III. Bradykinin: fragments and analogs.Canadian journal of biochemistry 56: 92-100.
Ramirez-Molina C, Heudi O, Pullen M, Marshall PS (2006). Study of bradykinin metabolism by rat lung tissue membranes and rat kidney brush border membranes by HPLC with inductively coupled plasma-mass spectrometry and orthogonal acceleration time-of-flight mass spectrometry. Journal of peptide science : an official publication of the European Peptide Society 12: 220-226.
Redman LW, Regoli D, Tustanoff ER (1979). Immunological and biological activities of fragments and analogs of bradykinin. Canadian journal of biochemistry 57: 529-539.
Regoli D, Gobeil F, Jr. (2015). Critical insights into the beneficial and protective actions of the kallikrein-kinin system. Vascular pharmacology 64: 1-10.
Regoli D, Gobeil F (2016). Kinins and peptide receptors.Biological chemistry 397: 297-304.
Regoli D, Barabe J, Park WK (1977). Receptors for bradykinin in rabbit aortae. Canadian journal of physiology and pharmacology55: 855-867.
Roch-Arveiller M, Caranikas S, Regoli D, Giroud JP (1983). Effects of bradykinin and some of its fragments on smooth muscles and chemotaxis.European journal of pharmacology 88: 99-103.
Rocha-Resende C, Leao NM, de Lima ME, Santos RA, Pimenta AMC, Verano-Braga T (2017). Moving pieces in a cryptomic puzzle: Cryptide from Tityus serrulatus Ts3 Nav toxin as potential agonist of muscarinic receptors. Peptides 98: 70-77.
Rocha-Resende C, Roy A, Resende R, Ladeira MS, Lara A, de Morais Gomes ER, et al. (2012). Non-neuronal cholinergic machinery present in cardiomyocytes offsets hypertrophic signals. J Mol Cell Cardiol53: 206-216.
Rocha ESM, Beraldo WT, Rosenfeld G (1949). Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. The American journal of physiology156: 261-273.
Ryan JW, Roblero J, Stewart JM (1968). Inactivation of bradykinin in the pulmonary circulation. The Biochemical journal 110:795-797.
Ryan JW, Berryer P, Chung AY, Sheffy DH (1994). Characterization of rat pulmonary vascular aminopeptidase P in vivo: role in the inactivation of bradykinin. The Journal of pharmacology and experimental therapeutics 269: 941-947.
Santos RAS, Oudit GY, Verano-Braga T, Canta G, Steckelings UM, Bader M (2019). The renin-angiotensin system: going beyond the classical paradigms. American journal of physiology. Heart and circulatory physiology 316: H958-H970.
Schneider CA, Rasband WS, Eliceiri KW (2012). NIH Image to ImageJ: 25 years of image analysis. Nature methods 9: 671-675.
Schoemaker RG, van Heijningen CL (2000). Bradykinin mediates cardiac preconditioning at a distance. American journal of physiology. Heart and circulatory physiology 278: H1571-1576.
Semis M, Gugiu GB, Bernstein EA, Bernstein KE, Kalkum M (2019). The Plethora of Angiotensin-Converting Enzyme-Processed Peptides in Mouse Plasma. Analytical chemistry 91: 6440-6453.
Suzuki K, Abiko T, Endo N (1969). Synthesis of every kinds of peptide fragments of bradykinin. Chemical & pharmaceutical bulletin17: 1671-1678.
Uhlen M, Zhang C, Lee S, Sjostedt E, Fagerberg L, Bidkhori G, et al. (2017). A pathology atlas of the human cancer transcriptome.Science 357.
van de Veerdonk FL, Netea MG, van Deuren M, van der Meer JW, de Mast Q, Bruggemann RJ, et al. (2020). Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.eLife 9.
Verano-Braga T, Martins ALV, Motta-Santos D, Campagnole-Santos MJ, Santos RAS (2020). ACE2 in the renin-angiotensin system. Clinical science 134: 3063-3078.
Wick MJ, Harral JW, Loomis ZL, Dempsey EC (2018). An Optimized Evans Blue Protocol to Assess Vascular Leak in the Mouse. Journal of visualized experiments : JoVE .
Yang HY, Erdos EG, Levin Y (1970). A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochimica et biophysica acta 214: 374-376.